ATE437893T1 - Fusionsprotein mit angiopoietinrezeptorbindung und einer multimerisationsdomäne - Google Patents

Fusionsprotein mit angiopoietinrezeptorbindung und einer multimerisationsdomäne

Info

Publication number
ATE437893T1
ATE437893T1 AT03760110T AT03760110T ATE437893T1 AT E437893 T1 ATE437893 T1 AT E437893T1 AT 03760110 T AT03760110 T AT 03760110T AT 03760110 T AT03760110 T AT 03760110T AT E437893 T1 ATE437893 T1 AT E437893T1
Authority
AT
Austria
Prior art keywords
fusion protein
receptor binding
multimerization domain
angiopoietin receptor
angiopoietin
Prior art date
Application number
AT03760110T
Other languages
English (en)
Inventor
Gou Young Koh
Original Assignee
Genexel Sein Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genexel Sein Inc filed Critical Genexel Sein Inc
Application granted granted Critical
Publication of ATE437893T1 publication Critical patent/ATE437893T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03760110T 2002-05-21 2003-05-21 Fusionsprotein mit angiopoietinrezeptorbindung und einer multimerisationsdomäne ATE437893T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38254102P 2002-05-21 2002-05-21
US10/273,180 US7081443B2 (en) 2002-05-21 2002-10-18 Chimeric comp-ang1 molecule
PCT/IB2003/003814 WO2003106501A1 (en) 2002-05-21 2003-05-21 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain

Publications (1)

Publication Number Publication Date
ATE437893T1 true ATE437893T1 (de) 2009-08-15

Family

ID=29552950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760110T ATE437893T1 (de) 2002-05-21 2003-05-21 Fusionsprotein mit angiopoietinrezeptorbindung und einer multimerisationsdomäne

Country Status (10)

Country Link
US (3) US7081443B2 (de)
EP (1) EP1549679B1 (de)
JP (1) JP4384597B2 (de)
KR (1) KR100611620B1 (de)
AT (1) ATE437893T1 (de)
AU (1) AU2003256001A1 (de)
CA (1) CA2486649C (de)
DE (1) DE60328615D1 (de)
DK (1) DK1549679T3 (de)
WO (1) WO2003106501A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
KR20060017585A (ko) * 2003-04-04 2006-02-24 유니베르시떼 드 로잔느 암 치료용 펩타바디
US20060024825A1 (en) * 2004-07-26 2006-02-02 Medipost Co. Ltd. Method of promoting expansion of stem cells
EP1819355A4 (de) * 2004-09-28 2009-08-12 Genexel Sein Inc Verfahren zur verwendung eines chimärischen coiled-coil-moleküls
US8346346B1 (en) 2005-01-24 2013-01-01 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
WO2007110001A2 (es) * 2006-03-29 2007-10-04 Centro De Ingenieria Genetica Y Biotecnologia Moléculas quiméricas fusionadas a matrilina 1, de uso terapéutico.
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
JPWO2008093827A1 (ja) * 2007-02-01 2010-05-20 財団法人大阪産業振興機構 中枢神経障害治療剤及び中枢神経障害の治療方法
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
JP2010532662A (ja) * 2007-07-06 2010-10-14 イントラダイム コーポレイション 癌および他の血管新生関連疾患の治療のための方法および組成物
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2478013B1 (de) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled-coil- und/oder tether-haltige proteinkomplexe und verwendungen davon
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
WO2012048009A2 (en) * 2010-10-05 2012-04-12 Massachusetts Institute Of Technology Nanostructured physically-associating hydrogels for injectable, responsive and tough biomaterials
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
EP2662447B1 (de) * 2012-05-09 2020-02-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Artifizielle Forisomenkörper mit SEO-F-Fusionsproteinen, pflanzliche oder Hefezellen mit Vektoren, die für diese Proteine codieren
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR101407730B1 (ko) 2012-11-23 2014-06-12 인하대학교 산학협력단 안지오포이에틴-4 단백질을 유효성분으로 포함하는 발기부전의 예방 또는 치료용 조성물
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
ES2867249T3 (es) 2015-11-06 2021-10-20 Regeneron Pharma Angiopoyetinas para usar en la promoción de la coagulación sanguínea y en el tratamiento de trastornos de la coagulación sanguínea
JP6957039B2 (ja) * 2016-09-06 2021-11-02 学校法人慶應義塾 融合タンパク質、構造体、捕集剤、捕集する方法、ｄｎａ、及びベクター
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
CN107033249B (zh) * 2017-05-16 2020-07-14 成都开乐药业有限公司 sTie2融合蛋白、其载体及含有sTie2融合蛋白的药物组合物
KR102005712B1 (ko) * 2018-01-15 2019-07-31 전남대학교산학협력단 다중화 요소 및 가용성 조절 기술의 접목을 통한 재조합 단백질 생산방법 및 이의 용도
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
JP2023515825A (ja) * 2020-02-28 2023-04-14 ノースウェスタン ユニバーシティ 血管疾患を治療するためのアンジオポエチン模倣物およびｔｉｅ２アゴニストとしての、ｃ４結合タンパク質ｃ末端セグメントとアンジオポエチン－１フィブリノゲン様ドメインとの間のキメラ融合
JP2023515827A (ja) * 2020-02-28 2023-04-14 ノースウェスタン ユニバーシティ 房水流出を高め、眼圧を減少させる方法
GB202108761D0 (en) * 2021-06-18 2021-08-04 Ikarovec Ltd Ocular disorders
KR20250039300A (ko) * 2023-09-11 2025-03-20 서울대학교병원 안지오포이에틴-1 융합 단백질 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
JP2657113B2 (ja) 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5922572A (en) 1994-01-25 1999-07-13 Human Genome Sciences, Inc. Polynucleotides encoding haemopoietic maturation factor
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
EP0799243A4 (de) 1994-11-28 1998-08-19 Wistar Inst p53 PROTEINE MIT VERÄNDERTEN TETRAMERISIERUNGSDOMÄNEN
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
IL143558A0 (en) 1998-12-23 2002-04-21 Regeneron Pharma Method of enhancing the biological activity of ligands
MXPA01007602A (es) * 1999-02-01 2003-06-24 Beth Israel Hospital Comp/tsp-1, comp/tsp-2 y otras proteinas quimericas..
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
WO2001047951A2 (en) 1999-12-23 2001-07-05 An-Go-Gen Inc. Angiopoietin analogs
WO2002002746A2 (en) 2000-06-29 2002-01-10 University Of Connecticut Coiled-coil mediated heterodimerization functional interaction trap
US20040115180A1 (en) 2001-03-06 2004-06-17 Mustapha Abdelouahed Carrier chimeric proteins targeted carrier chimeric proteins and preparation thereof
WO2003048185A2 (en) 2001-11-30 2003-06-12 Genvec, Inc. Angiopioetin related factors
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule

Also Published As

Publication number Publication date
CA2486649C (en) 2014-08-05
WO2003106501A1 (en) 2003-12-24
EP1549679A4 (de) 2006-06-21
JP2006504405A (ja) 2006-02-09
US7309586B2 (en) 2007-12-18
US7081443B2 (en) 2006-07-25
EP1549679B1 (de) 2009-07-29
US20030220476A1 (en) 2003-11-27
DK1549679T3 (da) 2009-10-26
US7691366B2 (en) 2010-04-06
KR20050004198A (ko) 2005-01-12
US20060074230A1 (en) 2006-04-06
US20080160574A1 (en) 2008-07-03
EP1549679A1 (de) 2005-07-06
DE60328615D1 (de) 2009-09-10
AU2003256001A1 (en) 2003-12-31
CA2486649A1 (en) 2003-12-24
KR100611620B1 (ko) 2006-09-01
JP4384597B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
ATE437893T1 (de) Fusionsprotein mit angiopoietinrezeptorbindung und einer multimerisationsdomäne
DE60203696D1 (de) Härtbare, schweissbare überzugszusammensetzungen
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
DE60041326D1 (de) Federantriebsvorrichtung für Türen, mit regelbarem Hebelarm der Feder
NO20071302L (no) Bindingdomene fusjonsproteiner
DE602004026241D1 (de) Prothese für das Schultergelenk.
IL177922A0 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
BR0208469B1 (pt) isqueiro.
NO20053363D0 (no) Malrettede enkle epitoper.
ES1048464Y (es) Mariposa de somier perfeccionada.
ATE407021T1 (de) Beschichtete ablagemappe
FI108743B (fi) Toimilaite, jossa on lisälaite
ES1052709Y (es) Calentador, endurecedor y rehabilitador de manos.
BR8201164Y1 (pt) central de aquecimento para aviário.
ES1048873Y (es) Descapsulador perfeccionado.
ES1049872Y (es) Azada perfeccionada.
ES1050018Y (es) Macetero perfeccionado.
UA8407S (uk) Елемент настройки эну-0,5-40
ES1055859Y (es) Encendedor falso.
ES1053223Y (es) Asiento perfeccionado.
ES1049375Y (es) Marcador perfeccionado.
ES1050318Y (es) Agenda de escritorio perfeccionada.
ES1047515Y (es) Estructura perfeccionada, para sillas-tumbona o similares.
ES1049337Y (es) Transportador bidireccional resonante.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties